Octreotide

Generic Name: Octreotide

Brand Names: Bynfezia, Mycapssa, Sandostatin

Drug Type: Biotech

Chemical Formula: -

CAS Number: 83150-76-9

Unique Ingredient Identifier: RWM8CCW8GP

Background: Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.

Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.

Indication: Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.

Associated Conditions: Acromegaly, Diarrhea, Metastatic Carcinoid Tumors

Associated Therapies: Long-term maintenance therapy

Clinical Trials

Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

Completed

Conditions: Variceal Hemorrhage
Kidney Injury
Cirrhosis, Liver

Interventions: Drug: Somatostatin
Drug: Terlipressin
Drug: Octreotide

First Posted Date: 2019-02-19

Last Posted Date: 2019-07-05

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 1682

Registration Number: NCT03846180

Locations: 🇨🇳
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Department of Gastroenterology, Air Force Hospital of Northern Theater Command, Shenyang, Liaoning, China
🇨🇳
Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

and more 11 locations

Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

Conditions: Gastric NET

First Posted Date: 2019-01-23

Last Posted Date: 2019-01-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT03812939

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Phase 4

Terminated

Conditions: Esophageal Varices
Bleeding Esophageal Varices
Liver Cirrhoses
Upper Gastrointestinal Bleeding

Interventions: Drug: Octreotide

First Posted Date: 2018-08-10

Last Posted Date: 2025-01-09

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 34

Registration Number: NCT03624517

Locations: 🇺🇸
University of Florida Health, Jacksonville, Florida, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
The Ohio state University, Columbus, Ohio, United States

and more 5 locations

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Phase 1

Terminated

Conditions: Acromegaly

Interventions: Drug: ONO-5788
Drug: ONO-5788 Placebo
Drug: Octreotide

First Posted Date: 2018-06-27

Last Posted Date: 2019-06-05

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 76

Registration Number: NCT03571594

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults

Early Phase 1

Completed

Conditions: Vascular Stiffness
Insulin Sensitivity

Interventions: Drug: Octreotide
Drug: Insulin
Drug: Dextrose 20% solution

First Posted Date: 2018-05-09

Last Posted Date: 2022-05-13

Lead Sponsor: University of Virginia

Target Recruit Count: 15

Registration Number: NCT03520569

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Phase 4

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Octreotide
Drug: LAR Lanreotide
Behavioral: Questionnaires

First Posted Date: 2017-09-21

Last Posted Date: 2023-11-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT03289741

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 4 locations

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

Phase 2

Terminated

Conditions: Major Liver Resection

Interventions: Drug: Octreotide
Other: Placebo

First Posted Date: 2017-06-07

Last Posted Date: 2024-02-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 23

Registration Number: NCT03179995

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States